Epic Sciences Has a New CEO
A private biotech company that develops cancer diagnostics, Epic Sciences, Inc. appointed Murali K. Prahalad, PhD, as the new CEO. Dr. Prahalad was formerly Vice President of Corporate Strategy at Life Technologies, where he helped shape the organic and inorganic investment priorities across Life Technologies’ research tools, clinical diagnostic and applied market portfolios. “We welcome Dr. Prahalad…as the company begins global development and commercialization of important new diagnostic tests for detecting cancer and personalizing and monitoring cancer treatments,” says Kim Kamdar, partner at Domain Associates.
InspireMD’s New Global Marketing VP
Medical device company, InspireMD, a leader in embolic protection stents, appointed David Blossom as Vice President of Global Marketing and Strategy. Blossom is a 25-year sales and marketing veteran with expertise in interventional devices. Prior to joining InspireMD, Blossom worked with several prestigious medical device companies. He was Vice President of marketing at Covidien /Aspect Medical Systems and Capella Medical Devices. He will be responsible for creating and overseeing the implementation of a global strategic marketing plan.
A leading biopharmaceutical company, CalciMedica appointed Michael Dunn as Senior VP, Corporate Development. With more than 25 years in the life sciences business and corporate development, Dunn will be responsible for corporate development. Dunn joins CalciMedica from Biocept, Inc., where he also served as Senior VP, Corporate Development.
Echo Therapeutics announced its CEO, President and Chairman of the Board, Dr. Patrick Mooney, is taking an immediate leave of absence. Robert Doman, a member of Echo’s Board of Directors, will serve as Executive Chairman and Interim CEO. Doman has more than 30 years of executive level, international and domestic management, business development and strategic planning experience, specifically in medical devices and pharmaceuticals.
Charlene Prounis, CEO and managing partner of Flashpoint Medica, has been selected by the Women’s Venture Fund to receive the organization’s Highest Leaf Award. The award is given annually to women executives who contribute significantly to their respective industries while assisting other women in developing the skills and resources for attaining their own business goals.
Kinex Pharmaceutical announced that Dr. David Hangauer accepted a full-time role as its Chief Science Officer. To accept, Dr. Hangauer took an early retirement from his academic duties at the University of Buffalo where he was an Associate Professor of Chemistry. According to the company, Kinex was founded on Dr. Hangauer’s research and he has continued to help Kinex evolve and grow since its inception.
LehmanMillet promoted Carolyn Morgan to President and Deborah Lotterman to Chief Creative Officer. Previously, Morgan managed the company’s West Coast location as Executive Vice President and Managing Director, tripling the size of that office. Lotterman formerly served as Executive Vice President, Account Management and Planning for the East Coast Location. She will now work for both the East and West Coast offices.
A clinical-stage biopharmaceutical company, MacroGenics elected Paul F. Costa as its new Chairman and Dr. David C. Stump is joining the Board of Directors as well. Costa was the former Chairman of the Board of Amylin Pharmaceuticals, Inc., and is the former President and Chief Executive Officer of Novartis U.S. Corporation. Stump was most recently Executive Vice President, R&D at Huna Genome Sciences, Inc.
Biotechnology company Neurotech Pharmaceuticals announced that renowned ophthalmology experts Eugene de Juan, Jr. and Lester Kaplan, PhD have joined the company’s Board of Directors. Additionally, former Allergan Vice President and Therapeutic Area Head for ophthalmology, Rhett Schiffman, MD, MS, MHSA, also joined as Chief Medical Officer. Dr. Schiffman will lead the overall clinical development strategy and design and execute the clinical programs.
Specialty pharmaceutical and diagnostic company, Prometheus appointed Lisa Miller to CEO. With more than 25 years of experience in the global diagnostic and devices industries, Miller most recently served as Corporate VP at DAKO, headquarted in Copenhagen, Denmark.
A privately held biopharmaceutical company, TetraLogic appointed three executives: J. Kevin Buchi as President and CEO; Pete A. Meyers as CFO; and Lesley Russell, MBChB, MRCP as COO. Buchi previously was Corporate VP, Global Branded Products at Teva Pharmaceuticals; Meyers was Managing Director, Co-Head of Global Healthcare Investment Banking at Deutsche Bank Securities Inc.; and Russell is a hematologist with more than 20 years experience in international pharmaceutical experience.
Trevena, a clinical stage pharmaceutical company, appointed Roberto Cuca as Senior Vice President and CFO. With 20 years experience in the pharmaceutical and biotechnology industries, Cuca’s experience is in effectively transitioning healthcare companies through phases of rapid growth.